A phase 2 clinical study of Small-mobile-stem-cell-therapy-SMSbiotech.
Latest Information Update: 11 Mar 2026
At a glance
- Drugs Small mobile stem cell therapy SMSbiotech (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 03 Mar 2026 According to the SMSbiotech Media Release, The company obtain an Investigational New Drug approval in the United States, and advance into Phase 2 clinical development.
- 03 Mar 2026 New trial record